OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Frances A. Collichio
Consultant or Advisory Role - Amgen
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Morphotek; Roche/Genentech
Thomas Amatruda
Other Remuneration - Amgen
Neil N. Senzer
No relevant relationships to disclose
Jason Chesney
Research Funding - Amgen
Keith A. Delman
No relevant relationships to disclose
Lynn E. Spitler
Consultant or Advisory Role - BioVex
Research Funding - Amgen; BioVex
Igor Puzanov
Honoraria - Amgen
Susan Doleman
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yining Ye
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ari M. Vanderwalde
Employment or Leadership Position - Amgen
Robert Coffin
Consultant or Advisory Role - Amgen
Howard Kaufman
Consultant or Advisory Role - Amgen
Research Funding - Amgen